An Oral BTK Pill Cut Relapses in Two Phase Three MS Trials With Full Data Still Unreleased

Novartis says remibrutinib beat teriflunomide on relapse rates in two Phase 3 MS trials, but has not released the underlying numbers.

Have A Referral?